Status:

RECRUITING

Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

Lead Sponsor:

M.D. Anderson Cancer Center

Conditions:

Cervical Large Cell Neuroendocrine Carcinoma

Cervical Neuroendocrine Carcinoma

Eligibility:

All Genders

Brief Summary

This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as pa...

Detailed Description

PRIMARY OBJECTIVES: I. To collect, both prospectively and retrospectively, data on disease characterization, treatment, and outcomes for patients with neuroendocrine carcinoma of the uterine cervix. ...

Eligibility Criteria

Inclusion

  • Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes:
  • Small cell neuroendocrine carcinoma
  • Large cell neuroendocrine carcinoma
  • Undifferentiated high-grade neuroendocrine carcinoma
  • Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study
  • Patients with all stages of disease are considered eligible
  • Patients who do not speak English can be eligible if accompanied by an institutional interpreter
  • Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible
  • Patient may be residents of any country and be of any ethnic background
  • Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website
  • Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate
  • Next of kin or legal authorized representatives of patients must read and speak English

Exclusion

  • Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors

Key Trial Info

Start Date :

May 16 2013

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

January 1 2044

Estimated Enrollment :

750 Patients enrolled

Trial Details

Trial ID

NCT04723095

Start Date

May 16 2013

End Date

January 1 2044

Last Update

September 10 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030